Clinical TrialJun 4, 2026, 07:02 AM
Fractyl Health Revita maintains 78% GLP-1 weight loss at one year
AI Summary
Fractyl Health announced positive one-year results from its open-label REVEAL-1 Cohort for the Revita procedure. Patients maintained approximately 78% of their GLP-1-induced weight loss one year after discontinuing GLP-1 therapy and undergoing a single Revita procedure, significantly outperforming the ~15% weight regain seen in third-party studies after GLP-1 withdrawal alone. The study also showed sustained glycemic control and excellent tolerability, with 33% of patients continuing to lose weight.
Key Highlights
- Participants retained ~78% of GLP-1 induced total body weight loss one year after Revita procedure.
- Mean total body weight change of 5.3% observed with Revita (n=15) at one year.
- 33% of patients continued to lose further weight one year after discontinuing GLP-1.
- 100% of patients maintained at least 5% of GLP-1-induced weight loss through one year.
- Minimal change in HbA1c levels (0.08%) observed after the Revita procedure.
- No procedure-related serious adverse events reported.
- Next data readouts: REMAIN-1 Midpoint Cohort in Q3 2026, REMAIN-1 Pivotal Cohort in early Q4 2026.
Price Impact
More from GUTS